NCT04427228
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have 1-10 newly diagnosed brain metastases with at least one lesion measuring greater than or equal to 0.5cm and no more than 3 cm in diameter; If multiple metastases are present, the other(s) must not exceed 3.0 cm in diameter
Exclusions: Patients with leptomeningeal disease; Patients with metastases in the brain stem, midbrain, pons, medulla, or within 7 mm of the optic apparatus (optic nerves, chiasm and optic tracts); Patients with a prior history of pseudoprogression or radionecrosis from cranial radiotherapy; Patients who have not received immunotherapy (PD-1/PD-L1 and/or CTLA-4 inhibitor(s) within the past 6 months and/or patients who are not planning to receiving immunotherapy within the next month
https://ClinicalTrials.gov/show/NCT04427228